A promising antifibrotic drug, pyridoxamine attenuates thioacetamide-induced liver fibrosis by combating oxidative stress, advanced glycation end products, and balancing matrix metalloproteinases

• Published in: European journal of pharmacology Vol. 923; p. 174910
• Main Authors: Alshanwani, Aliah R., Hagar, Hanan, Shaheen, Sameerah, Alhusaini, Ahlam M., Arafah, Maha M., Faddah, Laila M., Alharbi, Fatima MB, Sharma, Arun K., Fayed, Amel, Badr, Amira M.
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 15-05-2022
• Subjects: Advanced glycation end products; Liver fibrosis; Matrix metalloproteinases; Pyridoxamine; Tissue inhibitor of matrix metalloproteinase-1; Transforming growth factor-β; Advanced glycation end products; Matrix metalloproteinases; Liver fibrosis; Pyridoxamine; Transforming growth factor-β; Tissue inhibitor of matrix metalloproteinase-1
• ISSN: 0014-2999; 1879-0712
• DOI: 10.1016/j.ejphar.2022.174910

Liver fibrosis is a common chronic hepatic disease. This study was done to examine the effect of pyridoxamine against thioacetamide-induced hepatic fibrosis. Animals were divided into four groups (1) control group; (2) Thioacetamide group (200 mg/kg, i.p.) twice a week for eight weeks; (3) Pyridoxamine-treated group treated with pyridoxamine (100 mg/kg/day, i.p.) for eight weeks; (4) Thioacetamide and pyridoxamine group, in which pyridoxamine was given (100 mg/kg/day, i.p.) during thioacetamide injections. Thioacetamide treatment resulted in hepatic dysfunction manifested by increased serum levels of bilirubin, gamma-glutamyl transferase (GGT), alanine aminotransferase (ALT), and aspartate aminotransferase (AST). Oxidative stress was noted by increased hepatic lipid peroxidation and decreased glutathione (GSH). Increased concentrations of total nitrite/nitrate, advanced glycation end products (AGEs), monocyte chemoattractant protein-1 (MCP-1), tumor necrosis factor-α (TNF-α), transforming growth factor-β (TGF-β), matrix metalloproteinases (MMP-2&9) and tissue inhibitor of metalloproteinase-1 (TIMP-1) were noticed in hepatic tissues. Immunostaining sections also revealed overexpression of MMP-2, MMP-9 and collagen IV. Liver fibrosis was confirmed by severe histopathological changes. Pyridoxamine improved the assessed parameters. Moreover, histopathological and immunohistological studies supported the ability of pyridoxamine to reduce liver fibrosis. The findings of the present study provide evidence that pyridoxamine is a novel target for the treatment of liver fibrosis.